好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: an NF Clinical Trials Consortium study
Neuro-oncology
S23 - (-)
004
Authors/Disclosures
Scott R. Plotkin, MD, PhD, FAAN (Mass General Cancer Center)
PRESENTER
Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has stock in SonALAsense. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Nicole Ullrich, MD, PhD, MMSci, FAAN (Boston Children'S Hospital) Dr. Ullrich has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion Pharmaceuticals. The institution of Dr. Ullrich has received research support from Children's Tumor Foundation. Dr. Ullrich has received intellectual property interests from a discovery or technology relating to health care. Dr. Ullrich has received publishing royalties from a publication relating to health care.
Jeffrey C. Allen, MD, FAAN (NYU Langone Medical Center) No disclosure on file
Jaishri Blakeley, MD, FAAN (Johns Hopkins University School of Medicine) Dr. Blakeley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Springworks Therapeutics.
Tena Rosser, MD (Childrens Hospital Los Angeles) Dr. Rosser has received publishing royalties from a publication relating to health care. Dr. Rosser has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with Children's Tumor Foundation. Dr. Rosser has received personal compensation in the range of $500-$4,999 for serving as a Speaker/consultant with Springworks Therapeutics.
No disclosure on file
No disclosure on file
No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham) Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
Bruce R. Korf, MD (University of Alabama At Birmingham) Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SpringWorks Pharmaceuticals. Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Healx. Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Recursion. Dr. Korf has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genome Medical. Dr. Korf has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Infixion. Dr. Korf has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Journal of Human Genetics. Dr. Korf has stock in Genome Medical. The institution of Dr. Korf has received research support from NIH. The institution of Dr. Korf has received research support from Department of Defense. The institution of Dr. Korf has received research support from Children's Tumor Foundation. Dr. Korf has received publishing royalties from a publication relating to health care. Dr. Korf has received publishing royalties from a publication relating to health care. Dr. Korf has received publishing royalties from a publication relating to health care.
Roger J. Packer, MD (Children's National Medical Center, Neurology Dept) No disclosure on file
No disclosure on file
Matthias Karajannis No disclosure on file